H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on CorMedix (CRMD) to $18 from $17 and keeps a Buy rating on the shares post the Q3 report. With the acquisition of Melinta now closed, CorMedix has a more diversified business going into 2026, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD: